Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The present study will be a randomized, control, multicenter phase II study of metastatic
nasopharyngeal carcinoma (NPC) treated with evacizumab (AVASTIN,Roch) with paclitaxel and
carboplatin regimen (TC+AVASTIN) or carboplatin/paclitaxel alone (TC). The population
consists of metastatic nasopharyngeal carcinoma (NPC) that failed the radical radiotherapy or
chemotherapy-naïve advanced NPC (stage IV). The effectiveness and side effects will be
evaluated according to RECIST 1.1 and NCI-CTC AE V4.0.TEORTC QLQ-C30 and EORTC QLQ-H&N35 are
used to measure PRO outcome for this study.